2023-05-03 14:25:08 ET
- Organon ( NYSE: OGN ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open.
- The consensus EPS estimate is $1.16 and the consensus revenue estimate is $1.54B.
- Over the last 1 year, OGN has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time.
- Over the last 3 months, EPS estimates have seen 1 upward revision and 4 downward. Revenue estimates have seen 3 upward revisions and 1 downward.
- The company on Feb. 16 reported Q4 Non-GAAP EPS of $0.81, missing estimates by $0.10. Revenue of $1.49B was -6.9% Y/Y and missed consensus by $10M.
- OGN has a Quant rating of "Hold", with a 2.69 rating score.
- OGN has an industry ranking of 122 out of 221 among healthcare stocks, as per SA's Quant ranking.
- Wall Street analysts and Seeking Alpha authors rate the OGN stock "Buy".
- Recent Analysis: The Value Investor, leader of the " Value In Corporate Events " Investing Group on Seeking Alpha, wrote in a recently published report , "Organon has seen mostly margin disappointments since the spinoff from Merck. While the performance is not comforting, valuations are non-demanding. Leverage is high, but stabilization in the business, longer-term maturities, and fixed rates alleviate many leverage concerns."
- In mid-March, Raymond James launched its coverage on Organon with an "Outperform" recommendation citing its potential in the biosimilar space with the upcoming launch of Hadlima, a copycat version of AbbVie's blockbuster arthritis therapy Humira.
- Other analysis from our contributors: Don't Buy Viatris And Organon Just Because Of The Dividends by Deep Value Ideas.
- Organon: Too Cheap To Ignore by Gen Alpha, member of the " Hoya Capital Income Builder " Investing Group on Seeking Alpha.
- OGN stock fell 7% in 2022, while the benchmark S&P 500 index slipped nearly 20% for the year.
- Stock is down 13% so far this year as of Tuesday's close.
For further details see:
Organon Q1 2023 earnings on deck, what to expect